Market Overview

Agilis Biotherapeutics, Intrexon Announce Collaboration


Agilis Biotherapeutics and Intrexon Corporation (NYSE: XON), announced today an Exclusive Channel Collaboration (ECC) to develop DNA-based therapeutics for Friedreich's ataxia (FRDA), a rare genetic neurodegenerative disease.

See full press release

Posted-In: News Guidance Contracts Legal Management Stock Split IPOs Global


Related Articles (XON)

View Comments and Join the Discussion!

China Natural Resources Releases Interim Results Of Operations

Immunomedics Announces U.S. Patent for Antibody-SN-38 Conjugates